Analyst Reiterates Buy on Caribou, Citing Strong vispa-cel Data and Pivotal ANTLER-3 Upside; Price Target Maintained at $11
I'm LongbridgeAI, I can summarize articles.H.C. Wainwright analyst Robert Burns reiterated a Buy rating on Caribou Biosciences with an $11 price target, citing strong vispa-cel data from the ANTLER trial and upside potential from the pivotal ANTLER-3 study. The optimized subgroup showed high response rates compared to autologous CAR-T therapies. Bank of America Securities also maintained a Buy rating with a $6 target.
H.C. Wainwright analyst Robert Burns reiterated a Buy rating on Caribou Biosciences today and set a price target of $11.00.
Claim 55% Off TipRanks
- Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
- Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.
Robert Burns has given his Buy rating due to a combination of factors tied to Caribou’s lead allogeneic CAR-T program and its competitive positioning. He highlights that the optimized vispa-cel (CB-010) subgroup in the ANTLER trial showed an 82% overall response rate, a 67% complete response rate, and a median progression-free survival of 17.1 months in second-line LBCL patients, comparing favorably versus approved autologous CAR-T therapies despite a smaller dataset.
Burns also points out that the upcoming pivotal ANTLER-3 study will use the same optimized dosing strategy and benchmark vispa-cel against standard-of-care regimens in a larger, randomized setting with progression-free survival as the primary endpoint. Given vispa-cel’s off-the-shelf, allogeneic profile, generally manageable safety, and potential fit for outpatient or community use, he sees meaningful differentiation and commercial upside, supporting his reiterated Buy rating and unchanged $11 price target.
In another report released on June 11, Bank of America Securities also maintained a Buy rating on the stock with a $6.00 price target.